Education
About Us
Working with TipRanks
Follow Us
Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ:VNDA
VNDA Stock Chart & Stats
$7.78
-$0.20(-4.12%)
At close: 4:00 PM EST
$7.78
-$0.20(-4.12%)
Day’s Range― - ―
52-Week Range$3.81 - $9.60
Previous CloseN/A
Volume240.10K
Average Volume (3M)2.16M
Market Cap
$454.45M
Enterprise Value$395.98M
Total Cash (Recent Filing)$293.75M
Total Debt (Recent Filing)$6.23M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Feb 11, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding59,096,630
10 Day Avg. Volume734,414
30 Day Avg. Volume2,164,597
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.52
Price to Sales (P/S)1.40
P/FCF Ratio-17.14
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue1.87
Enterprise Value/Gross Profit1.99
Enterprise Value/Ebitda-3.90
Forecast
1Y Price Target
$13.63Price Target Upside75.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsControlled clinical trials showed consistent improvements in sleep duration, reduced time to persistent sleep, and improved next-day alertness, supporting the drug's therapeutic profile for sleep-related disorders.
Motion Sickness Commercial OpportunityTradipitant demonstrated consistent reductions in vomiting with a favorable safety profile, positioning it to become the first new pharmacologic option for motion sickness in decades and creating a differentiated commercial niche.
Pipeline Diversification Into Rare DermatologySubmission of a biologics application for imsidolimab in generalized pustular psoriasis expands the pipeline into a rare dermatology indication with high unmet need, offering potential upside beyond core sleep assets.
Bears Say
Constrained Initial Market StrategyAnalyst assumptions of an initial focus on sea travel would limit early sales scope and compress near-term revenue potential unless broader travel indications are secured.
Regulatory Refusal For Jet Lag IndicationThe FDA determined that clinical models did not sufficiently replicate actual jet travel conditions and refused approval for the jet lag indication, undermining near-term commercialization plans for the sleep drug.
Weak Financial Results And Expense PressureWeak quarterly revenue combined with higher operating expenses expanded the company's net loss, heightening concerns about cash burn and potential financing needs.
Vanda News
VNDA FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.81 and its highest was $9.60 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is $454.45M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Feb 11, 2026 which is in 12 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Oct 29, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.433 by $0.053.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.98.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 59,096,630 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.433. Following the earnings report the stock price went down -20.148%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VNDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vanda Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.63 (75.19% Upside)
$13.63 (75.19% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.19%
12-Months-Change
Fundamentals
Return on Equity
-16.72%
Trailing 12-Months
Asset Growth
-6.82%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
VNDA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong commercial execution and pipeline advancements, with significant growth in Fanapt sales and strategic investments in infrastructure. However, the financial performance was marred by a significant net loss and increased operating expenses. Overall, the positives in sales and pipeline progression were balanced by financial challenges.View all VNDA earnings summariesVNDA Stock 12 Month Forecast
Average Price Target
$13.63
▲(75.19% Upside)
Technical Analysis
Ownership Overview
7.36% Insiders
15.19% Mutual Funds
11.80% Other Institutional Investors
52.77% Public Companies and
Individual Investors